Logo image of IDYA

IDEAYA BIOSCIENCES INC (IDYA) Stock Fundamental Analysis

NASDAQ:IDYA - Nasdaq - US45166A1025 - Common Stock - Currency: USD

20.47  -0.46 (-2.2%)

After market: 20.47 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IDYA. IDYA was compared to 563 industry peers in the Biotechnology industry. IDYA has a great financial health rating, but its profitability evaluates not so good. IDYA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IDYA has reported negative net income.
In the past year IDYA has reported a negative cash flow from operations.
IDYA had negative earnings in each of the past 5 years.
In the past 5 years IDYA reported 4 times negative operating cash flow.
IDYA Yearly Net Income VS EBIT VS OCF VS FCFIDYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

With a decent Return On Assets value of -24.42%, IDYA is doing good in the industry, outperforming 73.00% of the companies in the same industry.
IDYA has a better Return On Equity (-25.91%) than 81.88% of its industry peers.
Industry RankSector Rank
ROA -24.42%
ROE -25.91%
ROIC N/A
ROA(3y)-18.98%
ROA(5y)-16.31%
ROE(3y)-20.3%
ROE(5y)-18.96%
ROIC(3y)N/A
ROIC(5y)N/A
IDYA Yearly ROA, ROE, ROICIDYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IDYA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IDYA Yearly Profit, Operating, Gross MarginsIDYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

IDYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IDYA has more shares outstanding than it did 1 year ago.
IDYA has more shares outstanding than it did 5 years ago.
IDYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IDYA Yearly Shares OutstandingIDYA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IDYA Yearly Total Debt VS Total AssetsIDYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 15.89 indicates that IDYA is not in any danger for bankruptcy at the moment.
IDYA has a Altman-Z score of 15.89. This is amongst the best in the industry. IDYA outperforms 92.01% of its industry peers.
There is no outstanding debt for IDYA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.89
ROIC/WACCN/A
WACC10.09%
IDYA Yearly LT Debt VS Equity VS FCFIDYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M 1B

2.3 Liquidity

IDYA has a Current Ratio of 14.97. This indicates that IDYA is financially healthy and has no problem in meeting its short term obligations.
IDYA has a better Current ratio (14.97) than 90.23% of its industry peers.
IDYA has a Quick Ratio of 14.97. This indicates that IDYA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IDYA (14.97) is better than 90.41% of its industry peers.
Industry RankSector Rank
Current Ratio 14.97
Quick Ratio 14.97
IDYA Yearly Current Assets VS Current LiabilitesIDYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for IDYA have decreased strongly by -67.51% in the last year.
IDYA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -70.06%.
IDYA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -36.96% yearly.
EPS 1Y (TTM)-67.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-186.54%
Revenue 1Y (TTM)-70.06%
Revenue growth 3Y-36.96%
Revenue growth 5YN/A
Sales Q2Q%78.43%

3.2 Future

Based on estimates for the next years, IDYA will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.17% on average per year.
The Revenue is expected to grow by 170.70% on average over the next years. This is a very strong growth
EPS Next Y13.88%
EPS Next 2Y8.98%
EPS Next 3Y8.42%
EPS Next 5Y19.17%
Revenue Next Year240.76%
Revenue Next 2Y270.2%
Revenue Next 3Y235.16%
Revenue Next 5Y170.7%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IDYA Yearly Revenue VS EstimatesIDYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IDYA Yearly EPS VS EstimatesIDYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IDYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IDYA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IDYA Price Earnings VS Forward Price EarningsIDYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDYA Per share dataIDYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.98%
EPS Next 3Y8.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IDYA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IDEAYA BIOSCIENCES INC

NASDAQ:IDYA (5/5/2025, 8:18:23 PM)

After market: 20.47 0 (0%)

20.47

-0.46 (-2.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)05-13 2025-05-13
Inst Owners109.03%
Inst Owner Change0.57%
Ins Owners0.91%
Ins Owner Change0.29%
Market Cap1.79B
Analysts86.32
Price Target52.7 (157.45%)
Short Float %12.32%
Short Ratio8.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-60.53%
Min EPS beat(2)-128.31%
Max EPS beat(2)7.25%
EPS beat(4)1
Avg EPS beat(4)-36.64%
Min EPS beat(4)-128.31%
Max EPS beat(4)7.25%
EPS beat(8)4
Avg EPS beat(8)-15.29%
EPS beat(12)7
Avg EPS beat(12)0.2%
EPS beat(16)7
Avg EPS beat(16)-16.55%
Revenue beat(2)1
Avg Revenue beat(2)-26.47%
Min Revenue beat(2)-100%
Max Revenue beat(2)47.06%
Revenue beat(4)1
Avg Revenue beat(4)-63.24%
Min Revenue beat(4)-100%
Max Revenue beat(4)47.06%
Revenue beat(8)3
Avg Revenue beat(8)-38.8%
Revenue beat(12)5
Avg Revenue beat(12)11.17%
Revenue beat(16)6
Avg Revenue beat(16)1.79%
PT rev (1m)-0.35%
PT rev (3m)-7.1%
EPS NQ rev (1m)2.91%
EPS NQ rev (3m)-0.17%
EPS NY rev (1m)2.32%
EPS NY rev (3m)-0.41%
Revenue NQ rev (1m)12.52%
Revenue NQ rev (3m)-32.97%
Revenue NY rev (1m)16.95%
Revenue NY rev (3m)-8.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 255.99
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB 1.69
EV/EBITDA N/A
EPS(TTM)-3.3
EYN/A
EPS(NY)-2.84
Fwd EYN/A
FCF(TTM)-2.87
FCFYN/A
OCF(TTM)-2.83
OCFYN/A
SpS0.08
BVpS12.1
TBVpS12.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.42%
ROE -25.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.98%
ROA(5y)-16.31%
ROE(3y)-20.3%
ROE(5y)-18.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 161.58%
Cap/Sales 55.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.97
Quick Ratio 14.97
Altman-Z 15.89
F-Score2
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)140.34%
Cap/Depr(5y)121.83%
Cap/Sales(3y)23.99%
Cap/Sales(5y)16.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-186.54%
EPS Next Y13.88%
EPS Next 2Y8.98%
EPS Next 3Y8.42%
EPS Next 5Y19.17%
Revenue 1Y (TTM)-70.06%
Revenue growth 3Y-36.96%
Revenue growth 5YN/A
Sales Q2Q%78.43%
Revenue Next Year240.76%
Revenue Next 2Y270.2%
Revenue Next 3Y235.16%
Revenue Next 5Y170.7%
EBIT growth 1Y-143.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.47%
EBIT Next 3Y-2.43%
EBIT Next 5YN/A
FCF growth 1Y-113.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-114.87%
OCF growth 3YN/A
OCF growth 5YN/A